Available in capsule or powder
for oral suspension

Rapid Release and 24-Hour Acid Control: Acid Reflux Medicine

ZEGERID gets into the bloodstream rapidly

As an acid reflux medicine, proton pump inhibitors work by getting into your blood stream and eventually shutting down some of the pumps that create acid.

ZEGERID is the First and Only Immediate-Release Proton Pump Inhibitor, providing rapid release of the active ingredients and continued 24-hour acid control.

In short, ZEGERID gets into your bloodstream rapidly. And one dose of this acid reflux drug a day provides 24-hour acid control.

Immediate Release or Delayed Release Acid Reflux Medicines

Except for ZEGERID, all proton pump inhibitors are delayed release acid reflux drugs. Delayed release proton pump inhibitors use a coating, called an enteric coating, to protect the acid reflux medicine from acid degradation while passing through the stomach. This coating delays the acid reflux medicine from getting into the bloodstream.

ZEGERID does not have an enteric coating and the acid reflux medicine is rapidly absorbed into the blood stream. That's why ZEGERID is the First and Only Immediate-Release oral Proton Pump Inhibitor.

Next page: Capsules or Powder

Product Description
ZEGERID contains omeprazole, a proton pump inhibitor (PPI), and sodium bicarbonate, an antacid.

Important Safety Information about ZEGERID
ZEGERID is indicated for the treatment of heartburn and other symptoms of acid reflux disease. ZEGERID is used to treat and maintain the healing of erosive esophagitis, which may result from acid reflux. ZEGERID is also indicated for the short-term treatment of active duodenal ulcer and of active benign gastric ulcer.

Side effects of ZEGERID include headache, diarrhea and abdominal pain. Relief of your symptoms while on ZEGERID does not rule out that other serious stomach conditions may exist.

ZEGERID Capsules contain 303 mg of sodium per dose. ZEGERID Powder for Oral Suspension contains 460 mg of sodium per dose. The sodium is in the form of sodium bicarbonate and these amounts should be taken into consideration by anyone on a sodium-restricted diet. People with metabolic alkalosis and hypocalcemia should not take sodium bicarbonate.

ZEGERID Capsules and ZEGERID Powder for Oral Suspension have the same amount of sodium bicarbonate in both the 20mg and 40mg dosages. Two 20mg doses are not equivalent to one 40mg dose, and two 20mg doses should not be used in place of one 40mg dose.

ZEGERID should not be taken by anyone with a known hypersensitivity to any component of the formulation.

To learn more about ZEGERID, see full prescribing information and talk with your doctor.

Please consult with your healthcare professional to see if ZEGERID is right for you. The content of this Web site is not a substitute for professional medical advice and should not be interpreted as treatment recommendations or relied on for medical diagnosis or treatment. Please see complete Legal Disclaimer.

Nexium is a trademark of AstraZeneca LP; Prevacid is a trademark of Tap Pharmaceutical Products, Inc.; Protonix is a trademark of Wyeth Pharmaceuticals Inc.; Prilosec is a trademark of Astra Merck Inc.; Aciphex is a trademark of Eisai Co., Ltd.